Aramchol Versus Placebo in the Treatment of HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy: A Randomized, Double-blinded, Allocation-concealed, Placebo-controlled Clinical Trial

Trial Profile

Aramchol Versus Placebo in the Treatment of HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy: A Randomized, Double-blinded, Allocation-concealed, Placebo-controlled Clinical Trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs Aramchol (Primary)
  • Indications Lipodystrophy; Non-alcoholic fatty liver disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ARRIVE
  • Sponsors Galmed Pharmaceuticals
  • Most Recent Events

    • 14 Feb 2018 Primary endpoint (Efficacy of Aramchol 600 mg vs. placebo in improving hepatic steatosis in patients with HIV-associated NAFLD) has not been met.
    • 27 Nov 2017 According to a Galmed Pharmaceuticals media release, foundations of the ARRIVE and ARREST clinical studies will be presented at at the 22nd biennial HEP DART meeting.
    • 09 Nov 2017 As of the beginning of November, 2017, all patients have been randomized in this trial, as reported in a Galmed Pharmaceuticals media release. Release of topline data is expected in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top